New drug combo aims to boost surgery success for esophageal cancer
NCT ID NCT07607210
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial is testing whether adding an experimental immunotherapy drug (SHR-1701) to standard chemotherapy can improve outcomes for people with a specific type of esophageal cancer (Siewert type II) that can be surgically removed. About 38 participants will receive the drug combination before and after surgery. The main goal is to see if the cancer is completely gone at the time of surgery (pathological complete response) and if the tumor can be fully removed (R0 resection).
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- SHR-1701 (an experimental immunotherapy drug) combined with chemotherapy (S-1 and oxaliplatin)
- What this could lead to
- If successful, this could offer a more effective treatment approach for this specific esophageal cancer, potentially increasing the chance of complete tumor removal during surgery.
- What could go wrong
- This is a small, early-phase trial (38 participants) with no results yet. The drug combination may cause significant side effects, and the benefit over standard treatment is unproven.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SIEWERT TYPE II ADENOCARCINOMA OF THE ESOPHAGOGASTRIC JUNCTION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The Fourth Hospital of Hebei Medical University
Shijiazhuang, Hebei, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.